Natural History of Human T-Lymphotropic Virus 1–Associated Myelopathy: A 14-Year Follow-up Study
The DOI matches its Crossref record.
Abstract
BACKGROUND: The progression of neurological disability in human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains undefined. OBJECTIVES: To determine the time course of disability scores and to identify predictors of outcome among patients with HAM/TSP. DESIGN: Clinical 14-year follow-up study. SETTING: University hospital. Patients One hundred twenty-three patients with HAM/TSP. MAIN OUTCOME MEASURES: We determined time from onset to the following 4 Kurtzke Disability Status Scale (DSS) end points: scores of 6 (unilateral aid required), 6.5 (bilateral aid required), 8 (wheelchair confinement), and 10 (death related to the disease). Times to reach selected DSS scores were estimated using the Kaplan-Meier method. Univariate and multivariate analyses identified variables related to the rate of progression to DSS 8. The HTLV-1 proviral loads were also assessed. RESULTS: The disability of the cohort progressed throughout the follow-up period. The median times from onset to DSS 6, 6.5, and 8 were 6, 13, and 21 years, respectively. The median time from DSS 6 to DSS 8 was 8 years; DSS 10 was reached by one fourth of the patients within 20 years. Age at onset of 50 years or older and high HTLV-1 proviral load were associated with a shorter time to DSS 8 (P = .01 and P = .02, respectively). A shorter time to DSS 6 significantly adversely affected the time to progression from DSS 6 to DSS 8. CONCLUSIONS: Human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis is a rapidly disabling disease. Monitoring for HTLV-1 proviral load is recommended in future therapeutic trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
HTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araujo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 279
Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1704827 · Cited by 113
Tanajura, D., Castro, N., Oliveira, P., Neto, A., Muniz, A., Carvalho, N. B., Orge, G., Santos, S., Glesby, M. J., & Carvalho, E. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ229 · Cited by 91
“in the pathogenesis of HTLV-1 infection [13, 31].”
BackgroundMartin, F., Fedina, A., Youshya, S., & Taylor, G. P. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.191239 · Cited by 70
Corticosteroid therapy in TSP/HAM patients: The results from a 10 years open cohort
Croda, M. G., de Oliveira, A. C. P., Vergara, M. P. P., Bonasser, F., Smid, J., Duarte, A. J. D. S., & Casseb, J. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.01.004 · Cited by 70
Metadata
- Authors
- Olindo, S., Cabre, P., Lézin, A., Merle, H., Saint-Vil, M., Signate, A., Bonnan, M., Chalon, A., Magnani, L., Cesaire, R., & Smadja, D.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-11-01
- Volume
- 63
- Issue
- 11
- Pages
- 1560
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2051266211
- Cited by
- 114
- References
- 0
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural History of Human T-Lymphotropic Virus 1–Associated Myelopathy: A 14-Year Follow-up Study. https://app.cochat.ai/papers/10.1001/archneur.63.11.1560
- The paper
- Olindo, S., Cabre, P., Lézin, A., Merle, H., Saint-Vil, M., Signate, A., Bonnan, M., Chalon, A., Magnani, L., Cesaire, R., & Smadja, D. (2006). Natural History of Human T-Lymphotropic Virus 1–Associated Myelopathy: A 14-Year Follow-up Study. Archives of Neurology. https://doi.org/10.1001/archneur.63.11.1560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.